ArticlePrzeglad gastroenterologiczny2019
Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club.
Article in Przeglad gastroenterologiczny, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Metachronous Primary Pancreatic Neuroendocrine Tumor and Adenocarcinoma: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- TRPV6-Mediated CaCancers · 2026Review
- Idiopathic chronic pancreatitis: clinical highlights.Therapeutic advances in gastroenterology · 2026Review
- Macrophage inhibitory cytokine 1, syncollin and thrombospondin-2 in pancreatic ductal adenocarcinoma and chronic pancreatitis differentiation.Frontiers in oncology · 2026Article
- Pancreatic Cancer Detection in Intraductal Papillary Mucinous Neoplasm (IPMN)-New Insights.Cancers · 2025Review
- Review
- Synaptophysin-like-1: A Novel Serum Diagnostic Marker for Pancreatic Ductal Adenocarcinoma Screening, Early Diagnosis, and Prognosis Prediction.Journal of clinical medicine · 2025Article
- Select Endocrine Disorders and Exosomes in Early PDAC Diagnosis.International journal of molecular sciences · 2024Review
- Robust and consistent biomarker candidates identification by a machine learning approach applied to pancreatic ductal adenocarcinoma metastasis.BMC medical informatics and decision making · 2024Article
- A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present.Biomolecules · 2024Review
- Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma.Cancers · 2023Article
- Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors.Journal of clinical medicine · 2023Review
- CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation.Journal of clinical medicine · 2023Article
- Endoscopic ultrasound-guided fine-needle aspiration pancreatic adenocarcinoma samples yield adequate DNA for next-generation sequencing: A cohort analysis.World journal of gastroenterology · 2023Article
- Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma.Cancers · 2023Review
- The progress of PET/MRI in clinical management of patients with pancreatic malignant lesions.Frontiers in oncology · 2023Review
- FES null mice demonstrate a reduction in neutrophil dependent pancreatic cancer metastatic burden.Frontiers in oncology · 2023Article
- Liquid biopsy leads to a paradigm shift in the treatment of pancreatic cancer.World journal of gastroenterology · 2022Review
- Synchronous Pancreatic Ductal Adenocarcinoma in the Head and Tail, a Double Trouble: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
These recommendations refer to the current management in pancreatic ductal adenocarcinoma (PDAC), a neoplasia characterised by an aggressive course and extremely poor prognosis. The recommendations regard diagnosis, surgical, adjuvant and palliative treatment, with consideration given to endoscopic and surgical methods. A vast majority of the statements are based on data obtained in clinical studies and experts' recommendations on PDAC management, including the following guidelines: International Association of Pancreatology/European Pancreatic Club (IAP/EPC), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network (NCCN) and Polish Society of Gastroenterology (PSG) and The National Institute for Health and Care Excellence (NICE)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.